IMMX

MKT CAP:$530M

Immix Biopharma, Inc.

Market Cap

$530M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$10.17+$4.74 (+87.29%)

Apr 23, 2026

Company Details

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phas...

CEO

Ilya Rachman

IPO Date

Dec 16, 2021

Website

www.immixbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$29M

EPS (Diluted)

-$0.89

Free Cash Flow

-$25M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 25, 2026

$0EPS -$0.89

Q4 2025

Mar 25, 2026

$0EPS -$0.28

Q3 2025

Nov 7, 2025

$0EPS -$0.24

Q2 2025

Aug 8, 2025

$0EPS -$0.22

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$0	$0	-$162.5K
Q2 21	$0	$0	-$243.2K
Q3 21	$0	$0	-$348.0K
Q4 21	$0	$0	-$598.3K
Q1 22	$0	$0	-$1M
Q2 22	$0	$0	-$2M
Q3 22	$0	$0	-$2M
Q4 22	$0	$0	-$4M
Q3 23	$0	$0	-$5M
Q2 24	$0	$0	-$5M
Q3 24	$0	$0	-$7M
Q4 24	$0	$0	-$5M
Q1 25	$0	$0	-$5M
Q2 25	$0	$0	-$7M
Q3 25	$0	$0	-$8M
Q4 25	$0	-$90.6K	-$11M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	-$266.4K	-$267.2K
Q2 21	-$158.0K	-$158.0K
Q3 21	-$50.8K	-$50.8K
Q4 21	-$1M	-$1M
Q1 22	-$1M	-$1M
Q2 22	-$547.1K	-$547.1K
Q3 22	-$1M	-$1M
Q4 22	-$4M	-$4M
Q3 23	-$3M	-$3M
Q2 24	-$5M	-$5M
Q3 24	-$4M	-$4M
Q4 24	-$1M	-$2M
Q1 25	-$2M	-$2M
Q2 25	-$5M	-$5M
Q3 25	-$6M	-$6M
Q4 25	-$11M	-$11M

Capital Expenditures

Quarter	CapEx
Q1 21	$802
Q2 21	$0
Q3 21	$0
Q4 21	$4
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$4
Q3 23	$38.9K
Q2 24	$97.1K
Q3 24	$271.5K
Q4 24	$507.2K
Q1 25	$67.7K
Q2 25	$127.6K
Q3 25	$372.5K
Q4 25	$165.1K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 21	—	+55.5%
Q2 21	—	+132.7%
Q3 21	—	+281.4%
Q4 21	—	+289.6%
Q1 22	—	+718.4%
Q2 22	—	+541.9%
Q3 22	—	+340.6%
Q4 22	—	+534.2%
Q3 23	—	+240.1%
Q2 24	—	+201.3%
Q3 24	—	+382.3%
Q4 24	—	+31.4%
Q1 25	—	+3.5%
Q2 25	—	+42.9%
Q3 25	—	+3.6%
Q4 25	—	+118.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$4.2K	—
Q2 21	$30.7K	—
Q3 21	$61.9K	—
Q4 21	$122.2K	—
Q1 22	$65.1K	—
Q2 22	$115.7K	—
Q3 22	$213.2K	—
Q4 22	$230.1K	—
Q3 23	$0	—
Q2 24	$637.9K	—
Q3 24	$733.8K	—
Q4 24	$705.7K	—
Q1 25	$868.4K	—
Q2 25	$532.2K	—
Q3 25	$470.5K	—
Q4 25	$570.8K	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 21	$24.8K	$137.7K
Q2 21	$62.8K	$180.4K
Q3 21	$29.7K	$318.3K
Q4 21	$9.2K	$589.1K
Q1 22	$629.5K	$700.5K
Q2 22	$607.8K	$953.2K
Q3 22	$695.9K	$837.4K
Q4 22	$2M	$2M
Q3 23	$2M	$2M
Q2 24	$2M	$2M
Q3 24	$4M	$3M
Q4 24	$1M	$4M
Q1 25	$2M	$3M
Q2 25	$4M	$3M
Q3 25	$5M	$3M
Q4 25	$6M	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$19M	$0	$19M
Q2 22	$18M	$0	$18M
Q3 22	$17M	$0	$17M
Q4 22	$13M	$0	$13M
Q1 23	$11M	$0	$11M
Q2 23	$13M	$0	$13M
Q3 23	$20M	$0	$20M
Q4 23	$18M	$0	$18M
Q1 24	$29M	$0	$29M
Q2 24	$24M	$0	$24M
Q3 24	$20M	$0	$20M
Q4 24	$18M	$0	$18M
Q1 25	$16M	$0	$16M
Q2 25	$12M	$0	$12M
Q3 25	$16M	$0	$16M
Q4 25	$94M	$6M	$100M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	9M	+15.8%	+160.0%
Q2 21	9M	0.0%	+160.0%
Q3 21	7M	-17.9%	-5.0%
Q4 21	8M	+5.2%	0.0%
Q1 22	14M	+82.6%	+57.6%
Q2 22	14M	+0.4%	+58.2%
Q3 22	14M	+0.3%	+93.4%
Q4 22	13M	-5.0%	+74.6%
Q3 23	19M	+40.4%	+34.3%
Q2 24	29M	+54.9%	+107.4%
Q3 24	29M	+2.2%	+111.3%
Q4 24	28M	-6.4%	+108.2%
Q1 25	30M	+7.8%	+59.9%
Q2 25	30M	+1.0%	+4.2%
Q3 25	32M	+6.5%	+8.5%
Q4 25	38M	+19.9%	+39.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	—	—
Q2 21	—	—
Q3 21	—	—
Q4 21	$0	2
Q1 22	$0	2
Q2 22	$0	2
Q3 22	$0	2
Q4 22	$0	11
Q3 23	$0	11
Q2 24	$0	17
Q3 24	$0	17
Q4 24	$0	21
Q1 25	$0	21
Q2 25	$0	21
Q3 25	$0	21
Q4 25	$0	200K

Revenue / Employee